Dr. Mikhail Blagosklonny and Dr. Andrei Gudkov started the online medical journal Oncotarget in 2010. The journal, which is published by Impact Journals, is peer-reviewed and is open access. Dr. Blagsklonny and Dr. Gudkov serves as the journal’s co-editors-in-chief.
Originally, Oncotarget was focused on the field of Oncology. More recently, the medical journal has opened up to publishing research papers from other fields of medicine as well including Metabolism, Pharmacology, Cardiology, and Endocrinology among others. The success of Oncotarget has been attributed to insightful and constructive research papers they publish, as well as having multiple peer-reviewers for each paper.
The mission of Oncotarget is to make research broadly available as well as punctually published. Dr. Gudkov and Dr. Blagosklonny believe that this approach will lead to better research and new discoveries. They also opened up the medical journal to other medical disciplines in order to break down the borders that exist between different fields of medicine and a desire to create a more collaborative spirit. The end goal of publishing Oncotarget is to end disease as we know it.
Both Dr. Gudkov and Dr. Blagosklonny are professors and researchers at the Roswell Park Cancer Institute. Both are primarily focused on oncology and developing therapies to cure cancer. Dr. Blagosklonny is particularly interested in researching the often used cancer drug rapamycin for not only further cancer research but also the role it can play in life extension. Learn more about Oncotarget journal at Bioxbio.com.
As a medical journal dedicated to providing timely and accurate research papers, Oncotarget has a robust ethics and malpractice regimen that it follows. The medical journal’s website spells out all of the duties and responsibilities for everyone involved in publishing research. This includes the author, reviewers, editors, and publisher. Among the standards that Oncotarget follows are the COPE Code of Conduct and Best Practice Guidelines for Journal Editors and other medical journal industry standards.